Viewing nowValsabel Tablets 40 mg (Valsartan)
Valsartan 40mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

MFDS item code 200904514 · Notified 2009.06.26 · Insurance code 643305150
Treatment of essential hypertension; reduction of the risk of death after myocardial infarction; treatment of heart failure
This medication is used to control blood pressure in patients with essential hypertension. It also helps improve symptoms in heart failure patients who are intolerant to ACE inhibitors, particularly those classified as NYHA class II to IV. It is effective in reducing the risk of death in patients with left ventricular dysfunction or reduced contractility following a myocardial infarction. In summary, it is used for essential hypertension, heart failure (especially in cases of intolerance to ACE inhibitors), and reducing mortality risk after myocardial infarction.
1. Essential hypertension Take with water during a meal or between meals. If possible, take it at the same time each day (e.g., in the morning). 1) Adults: Regardless of sex or race, an oral dose of valsartan 80 mg once daily is recommended. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg daily or a diuretic may be given concomitantly. If further blood pressure reduction is required, the dose may be increased to a maximum of 320 mg daily. 2) Elderly patients (75 years or older): Start treatment with 40 mg of this medicine once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dose adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Start treatment with 40 mg of this medicine once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this medicine. 4) Patients with volume depletion: In patients with volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), start treatment with 40 mg of this medicine once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, start treatment with 40 mg of this medicine once daily; do not exceed 80 mg daily. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended starting dose is 40 mg of this medicine orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When administered concomitantly with a diuretic, consider reducing the diuretic dose. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this medicine, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be started within 12 hours of the onset of myocardial infarction. The recommended starting dose is 20 mg of this medicine twice daily. Thereafter, over several weeks, increase the dose according to the patient's tolerability, administering 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This medicine may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytics, acetylsalicylic acid, beta-blockers, and statins). However, concomitant use with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dose adjustment is necessary for creatinine clearance of 10 mL/min or higher. However, do not administer this medicine to patients with creatinine clearance less than 10 mL/min or patients on dialysis, as there is no experience with its use in these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, it is preferable that the daily dose of this medicine not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this medicine to patients with severe hepatic impairment, cirrhosis, or cholestasis.
1. Essential hypertension 6) Children: The safety and efficacy have not been established in children and adolescents under 18 years of age. 6. Children: The safety and efficacy have not been established in children and adolescents under 18 years of age.
This medication can cause serious harm to the fetus and newborn, especially during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Women who are pregnant or may become pregnant, as well as nursing mothers, should not take this medication. It should not be used by patients with severe liver dysfunction, cirrhosis, or biliary obstruction. Additionally, patients with hereditary angioedema or a history of angioedema while receiving ACE inhibitors or angiotensin II receptor antagonists should not use this medication. Patients with severe renal impairment are also advised against using this drug. In diabetic patients with moderate to severe renal impairment, it should not be used in combination with certain medications. The elderly, patients with hyperkalemia, and those with mild to moderate liver impairment should use this medication cautiously, and dosage adjustment may be necessary. Patients with heart valve disease or cardiovascular disease, patients with fluid depletion, and patients with renal artery stenosis also require caution. Patients with heart failure or post-myocardial infarction should have their renal function periodically assessed before and during treatment, as changes in renal function may occur. Blood pressure may drop rapidly, so dosing should be started at a low level and gradually increased while closely monitoring the patient's condition. This medication may increase serum potassium levels, so patients with hyperkalemia should avoid or use it with caution, and potassium levels should be frequently monitored when taken with potassium-sparing diuretics or potassium supplements. Interactions may occur when used in combination with other antihypertensive medications or multiple drugs, so it must be taken as directed by a physician. Symptoms such as dizziness or drowsiness may occur, necessitating caution when driving or operating machinery. The safety and efficacy of this medication in children and adolescents have not been established, thus it is advisable for those under 18 not to use it. In case of overdose, symptoms such as hypotension or decreased consciousness may appear, requiring immediate medical attention for appropriate treatment. This medication should be kept out of the reach of children and should not be transferred to another container.
headache
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air and moisture from entering, and it should be kept in a cool place below 30 degrees centigrade, avoiding high temperatures and humidity. This will help maintain the effectiveness of the medication over time.
Yellow oval-shaped film-coated tablets
28 tablets (14 tablets per PTP × 2)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowValsartan 40mg
Tablet · Prescription medication
Jongkundang Co., Ltd.

Valsartan 80mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 160mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.

Valsartan 40mg
Tablet · Prescription medication
Samsung Novartis Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.
Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan
Prescription medication
Korea Sandos Co., Ltd.

Valsartan 320mg
Tablet · Prescription medication
Novartis Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.